Print this page    •   Back to Web version of article

The Body Covers: The 12th International AIDS Conference

Worldwide Issues on HIV/AIDS
Briefing on the Journal of the American Medical Association's HIV/AIDS Issue

Coverage provided by Michael Giordano, M.D.

June 27, 1998

On the eve of the opening of the 12th World AIDS Conference in Geneva, the American Medical Association held a day-long briefing on the research presented in the July 1st, "all-HIV" edition of JAMA. The briefing allowed the researchers whose work is being published to present information in lay terms to the press and public. Two key presentations covered:

Simultaneous vs. Sequential Initiation of Therapy with Indinavir (Crixivan), Zidovudine (AZT) and Lamuvidine (3TC) for HIV Infection: 100 Week Follow-Up

Presented by:
Roy Gulick, MD, MPH, Assistant Professor of Medicine, Cornell University Medical College, New York
Coverage by Michael Giordano, M.D.

At the last international AIDS conference in 1996 in Vancouver, Dr. Gulick presented early (24-week) data from this study of AZT, 3TC and the protease inhibitor indinavir (Crixivan) that showed the world how encouraging triple combination therapy could be. Now, this study of 97 patients has the longest follow-up to date of a combination HIV drug regimen.

This important presentation of two-year data from the study (known as Protocol 035) included the following points:

The study also taught important lessons on how to use antiretrovirals in combination. Patients who started with simultaneous therapy (i.e., starting all the drugs at the same time) had a significantly better chance of reaching undetectable than people who started the three drugs sequentially (adding one drug after another over time). Adding the drugs one at a time over several months kept HIV undetectable in only 30% - 45% of patients for 100 weeks. The study concluded that using drugs sequentially is a major cause of the treatment failure that has been reported increasingly in the medical and popular media. This study should encourage doctors and patients to learn to use potent drugs like indinavir in combination therapy properly, in order to gain maximum benefit from them.

Perinatal HIV-1 Transmission: Interaction between Zidovudine Prevention and Mode of Delivery in the French Perinatal Cohort

Presented by:
Laurent Mandelbrot, MD, of Hopital Cochin-Port Royal, Paris
Coverage by Michael Giordano, M.D.

In this study of 2,834 pairs of mothers and infants, this French study team found that HIV-positive pregnant women may have the best chance of preventing transmission of HIV to their baby by having an elective cesarean section (before the beginning of contractions and labor), using AZT while pregnant, and receiving intravenous AZT during delivery.

This study found that:

Earlier studies conducted in the United States have shown that AZT use during pregnancy does reduce the likelihood of HIV transmission from mother to child. The analysis of this study suggests that C-section and AZT therapy complement each other by protecting the baby at various stages of the gestation and birth process: during pregnancy, during the beginning of labor, and during delivery, when a great deal of blood is often present.

This study pointed out that a C-section is still major surgery, and may pose a significant risk to the mother, but it is a remarkably effective option that HIV-positive women who want to have a child may wish to discuss with their obstetricians.

This article was provided by Copyright Body Health Resources Corporation. All rights reserved.

You can find this article online by typing the following address into your Web browser:

Please Note: Knowledge about HIV changes rapidly. Note the date of this article's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this article.

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your healthcare provider.